Novartis to build biotech facility in Singapore

- Last updated on GMT

Related tags: Medicine

Novartis invests in Singapore
Novartis invests in Singapore
Novartis will spend $500m on a new cell-culture based manufacturing facility in Singapore.

The new biologics plant, which is due to be operational by 2016, will be built next to a solid dose pharmaceutical production facility that Novartis set up at the Tuas Biomedical Park​ in 2005.

The plan is to handle clinical and commercial production of monoclonal antibody-based medicines for autoimmune, respiratory and oncology indications.

CEO Joe Jimenez said that: "We have chosen Singapore as strategic supply point as it offers a wide range of advantages due to its strong local biomedical presence and knowledge, skilled labour as well as proximity to growth markets in Asia." asked Novartis if the plant is different from the one it said it would build in 2007​, but the firm did not respond to the request for information.

Related topics: Contract Manufacturing & Logistics

Related news

Show more

Follow us


View more